Eric Hsu
Corporate Officer/Principal bij INMED PHARMACEUTICALS INC.
Vermogen: 15 $ op 31-05-2024
Actieve functies van Eric Hsu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| INMED PHARMACEUTICALS INC. | Corporate Officer/Principal | 13-03-2018 | - |
Loopbaan van Eric Hsu
Eerdere bekende functies van Eric Hsu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Operationeel Directeur | 01-01-2002 | 01-01-2018 |
| Hoofd Techniek/Wetenschap/O&O | 01-01-2002 | 01-01-2018 |
Opleiding van Eric Hsu
| McGill University | Undergraduate Degree |
| University of Toronto | Doctorate Degree |
Statistieken
Internationaal
| Canada | 5 |
Operationeel
| Chief Operating Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INMED PHARMACEUTICALS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
